Artal Group S.A. recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
Artal Group S.A. is a holding company based out of Luxembourg, Luxembourg. The company was originally established in 1986 and has grown through both organic means and through various mergers and acquisitions. Artal Group S.A. would grow to have locations in France and Belgium on the international scale outside of the founding country and additional offices in Luxembourg as well. The company invests in a wide range of sectors, allocating its assets in both the stocks of companies and taking an active role in finding full ownerships in various food, textile, and, to a somewhat lesser degree, new technology companies. Artal Group S.A. invests most heavily in the consumer staples sector, which alone makes up over a third of the firm’s total asset allocations, and also invests in the health care sector, which makes up over another quarter of the firm’s allocations, consumer discretionary sector, and finance sector, among other sectors such as the information technology sector to a lesser degree, in order of decreasing allocations. The company holds its allocations for approximately 4.5 quarters on average and holds its top 10 allocations for the same amount of time. Artal Group S.A., in the most recent quarter, has had a turnover rate of approximately 33.3%. The company’s top 10 holdings together make up over three quarters of the firm’s total holdings and includes Blue Buffalo Pet Products Inc., the company’s biggest holding which alone makes up over a third of the firm’s total allocations, Lexicon Pharmaceuticals Inc., and Weight Watchers International, Inc. Outside of the previously mentioned three top holdings, none of the company’s holdings make up over 3% of the firm’s total allocations. Artal Group S.A. is related to the Invus Group which operates on an international scale. Invus Group has stated that, since its founding in 1985, its source of capital has been through a European family group, which, in turn, is mainly through the Artal investment vehicle.
As of the latest 13F report, the guru’s equity portfolio contained 137 stocks valued at a total of $2,388,000,000. The top holdings were ARGX(7.76%), WW(6.35%), and LXRX(6.23%).
According to GuruFocus data, these were Artal Group S.A.’s top five trades of the quarter.
argenx SE
During the quarter, Artal Group S.A. bought 87,500 shares of NAS:ARGX for a total holding of 587,500. The trade had a 1.16% impact on the equity portfolio. During the quarter, the stock traded for an average price of $290.58.
On 05/12/2022, argenx SE traded for a price of $288.62 per share and a market cap of $16,899,132,000. The stock has returned 10.53% over the past year.
GuruFocus gives the company a financial strength rating of 10 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, argenx SE has a price-book ratio of 6.82, a EV-to-Ebitda ratio of -43.58 and a price-sales ratio of 38.45.
The price-to-GF Value ratio is 0.65, earning the stock a GF Value rank of 8.
Seagen Inc
During the quarter, Artal Group S.A. bought 150,000 shares of NAS:SGEN for a total holding of 650,000. The trade had a 0.9% impact on the equity portfolio. During the quarter, the stock traded for an average price of $135.09.
On 05/12/2022, Seagen Inc traded for a price of $126.35 per share and a market cap of $26,285,853,000. The stock has returned -14.11% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Seagen Inc has a price-book ratio of 8.79, a EV-to-Ebitda ratio of -40.44 and a price-sales ratio of 15.64.
The price-to-GF Value ratio is 0.82, earning the stock a GF Value rank of 10.
Amicus Therapeutics Inc
Artal Group S.A. reduced their investment in NAS:FOLD by 2,000,000 shares. The trade had a 0.63% impact on the equity portfolio. During the quarter, the stock traded for an average price of $9.39.
On 05/12/2022, Amicus Therapeutics Inc traded for a price of $7.305 per share and a market cap of $2,861,960,000. The stock has returned -34.48% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Amicus Therapeutics Inc has a price-book ratio of 11.97, a EV-to-Ebitda ratio of -14.57 and a price-sales ratio of 8.91.
The price-to-GF Value ratio is 0.44, earning the stock a GF Value rank of 2.
IGM Biosciences Inc
During the quarter, Artal Group S.A. bought 500,000 shares of NAS:IGMS for a total holding of 2,000,000. The trade had a 0.56% impact on the equity portfolio. During the quarter, the stock traded for an average price of $18.63.
On 05/12/2022, IGM Biosciences Inc traded for a price of $14.6 per share and a market cap of $686,253,000. The stock has returned -79.93% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, IGM Biosciences Inc has a price-book ratio of 2.08 and a EV-to-Ebitda ratio of -3.13.
Novagold Resources Inc
The guru sold out of their 2,600,000-share investment in AMEX:NG. Previously, the stock had a 0.48% weight in the equity portfolio. Shares traded for an average price of $7.03 during the quarter.
On 05/12/2022, Novagold Resources Inc traded for a price of $5.315 per share and a market cap of $1,684,275,000. The stock has returned -43.47% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, Novagold Resources Inc has a price-book ratio of 25.25 and a EV-to-Ebitda ratio of -47.23.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
